インフリキシマブの中国市場（2022年～2031年）

中国のインフリキシマブの売上高は、2017年～2021年の間に約19.0％で成長し、2021年には3億3,589万人民元に達しました。

中国政府の厳格な「ゼロコロナ」政策の実施により、中国におけるインフリキシマブの販売量と販売額は2022年に減少すると予測されます。しかし、2023年初頭以降は、COVID-19管理政策を緩和すると予想されるため、2023年～2026年にかけて回復成長を見せると考えられます。

当レポートでは、中国のインフリキシマブ市場について調査分析し、COVID-19の影響、市場規模、メーカー分析、市場の見通しなどの情報を提供しています。

第1章 インフリキシマブの関連概念

• インフリキシマブの適応症
• 中国におけるインフリキシマブの開発
• 中国におけるインフリキシマブの政府承認
• 中国におけるインフリキシマブの販売に対するCOVID-19の影響

第2章 中国でのインフリキシマブの売上（2017年～2021年）

• インフリキシマブの売上高
  • 全体の売上高
  • 地域別の売上高
• インフリキシマブの販売量
  • 全体の販売量
  • 地域別の販売量
• 中国におけるインフリキシマブの販売：投与方法別（2017年～2021年）
  • 注射
  • その他の投与方法の分析

第3章 中国の主要なインフリキシマブメーカーの分析（2017年～2021年）

• 主要なインフリキシマブメーカーの市場シェア分析
  • 市場シェア調査：売上高別
  • 市場シェア調査：販売量別
• Janssen Biologics BV
  • 企業プロファイル
  • 中国でのREMICADE（Janssen 社のインフリキシマブ）の販売

第4章 中国のさまざまなメーカーのインフリキシマブの価格（2021年～2022年）

• Janssen Biologics BV (REMICADE)

第5章 中国のインフリキシマブ薬市場の見通し（2022年～2031年）

• 中国のインフリキシマブ市場開発の影響因子
  • 中国のインフリキシマブ市場に対するCOVID-19の影響
  • 市場促進要因と機会
  • 市場の脅威と課題
• 市場規模の予測
• 市場動向の予測

List of Charts

• Chart Infliximab Drugs Approved by Chinese Government, by 2022
• Chart Sales Value of Infliximab in China, 2017-2021
• Chart Sales Value of Infliximab in Regions of China, 2017-2021
• Chart Sales Volume of Infliximab in China, 2017-2021
• Chart Sales Volume of Infliximab in Regions of China,2017-2021
• Chart Sales value and volume of infliximab injection in China 2017-2021
• Chart Market Share of TOP3 Infliximab Manufacturers by Sales Value in China, 2017-2021
• Chart Market Share of TOP3 Infliximab Manufacturers by Sales Volume in China, 2017-2021
• Chart Profile of Janssen Biologics BV
• Chart Sales Value of Janssen Biologics BV 's Infliximab in China, 2017-2021
• Chart Sales Volume of Janssen Biologics BV 's Infliximab in China, 2017-2021
• Chart Profile of Taizhou Mabtech Pharmaceutical Co., Ltd.
• Chart Sales Value of Taizhou Mabtech Pharmaceutical Co., Ltd.'s Infliximab in China, 2017-2021
• Chart Sales Volume of Taizhou Mabtech Pharmaceutical Co., Ltd. 's Infliximab in China, 2017-2021
• Chart Hisun Biopharmaceutical Co., Ltd.
• Chart Sales Value of Xi'an Hanfeng Pharmaceutical Co., Ltd.'s Infliximab in China, 2017-2021
• Chart Sales Volume of Xi'an Hanfeng Pharmaceutical Co., Ltd.'s Infliximab in China, 2017-2021
• Chart Prices of Janssen Biologics BV's Infliximab (Remicade ®) in Parts of China, 2021-2022
• Chart Prices of Taizhou Mabtech Pharmaceutical Co., Ltd.'s Infliximab (Leiting®) in Parts of China, 2021-2022
• Chart Prices of Hisun Biopharmaceutical Co., Ltd.'s infliximab(Anbaite®) in Parts of China, 2021-2022
• Chart Forecast on sales of infliximab in China 2022-2031

Infliximab is a human-mouse chimeric IgG1 monoclonal antibody targeting tumor necrosis factor (TNF-α) (composed of human IgG1 constant region and mouse variable region). It is used to treat a variety of autoimmune diseases, including Crohn's disease, ulcerative colitis, rheumatoid arthritis, and ankylosing spondylitis. Infliximab was developed by Johnson & Johnson. In 2007, Infliximab entered the Chinese market. The Chinese infliximab market is completely dominated by Janssen, a Johnson & Johnson company, until 2021. Two local Chinese companies, Taizhou Mabtech Pharmaceutical Co., Ltd. and Hisun Biopharmaceutical Co., Ltd. are launching infliximab in 2021, making Janssen's infliximab a challenge in the Chinese market.

According to CRI's market research, since Infliximab entered the Chinese market in 2007, its sales have had an increasing trend. However, the sales in China are suboptimal compared to global sales. The main reason is that most patients in China cannot afford the expensive price. After Infliximab was included in the national medical insurance in 2019, the sales increased about 18.9% in 2020 and reached CNY335.89 million in 2021. The CAGR of infliximab's sales value in China is approximately 19.0% from 2017 to 2021.

According to CRI's market research and expert interviews, CRI sees different trends in 2022 and from 2023 to 2026 in China's infliximab market.

Sales volume and value of infliximab in China are expected to decline in 2022 as the Chinese government implements a strict "COVID-19 dynamic zeroing" policy that will prevent many healthcare facilities in China from operating normally. It is expected that the Chinese government will relax the COVID-19 control policy from early 2023 onwards, and thus the sales volume and sales value of infliximab in China will show a recovery growth from 2023-2026.

Topics covered:

• The impact of COVID-19 on China's Infliximab market

• Sales value of China's Infliximab 2017-2021

• Competitive landscape of China's Infliximab market

• Prices of Infliximab in China

• Prices of Infliximab in China by regions and manufacturers

• Analysis on factors affecting the development of China's Infliximab market

• Prospect of China's Infliximab market from 2022 to 2026

Table of Contents

1 Relevant Concepts of Infliximab

• 1.1 Indications for Infliximab
• 1.2 Development of Infliximab in China
• 1.3 Governmental Approval of Infliximab in China
• 1.4 The Impact of COVID-19 on Infliximab sales in China

2 Sales of Infliximab in China, 2017-2021

• 2.1 Sales Value of Infliximab
  • 2.1.1 Overall Sales Value
  • 2.1.2 Sales Value by Region
• 2.2 Sales Volume of Infliximab
  • 2.2.1 Overall Sales Volume
  • 2.2.2 Sales Volume by Regions
• 2.3 Sales of Infliximab by Dosage Form in China, 2017-2021
  • 2.3.1 Injection
  • 2.3.2 Analysis of Other Dosage Forms

3 Analysis of Major Infliximab Manufacturers in China, 2017-2021

• 3.1 Analysis of Market Share of Major Infliximab Manufacturers
  • 3.1.1 Investigation on Market Share by Sales Value
  • 3.1.2 Investigation on Market Share by Sales volume
• 3.2 Janssen Biologics BV
  • 3.2.1 Enterprise Profile
  • 3.2.2 Sales of REMICADE (Janssen's Infliximab) in China

4 Prices of Infliximab for Different Manufacturers in China, 2021-2022

• 4.1 Janssen Biologics BV (REMICADE)

5 Prospect of Chinese Infliximab drug Market, 2022-2031

• 5.1 Influential Factors of Chinese Infliximab Market Development
  • 5.1.1 The Impact of COVID-19 on Chinese Infliximab Market
  • 5.1.2 Market Drivers and Opportunities
  • 5.1.3 Market Threats and Challenges
• 5.2 Forecast on Market Size
• 5.3 Forecast on Market Trend